Literature DB >> 10091034

Vancomycin-resistant enterococci: the clinical effect of a common nosocomial pathogen.

P K Linden1, C B Miller.   

Abstract

Enterococcus spp. is now the third most common pathogen among hospitalized patients, accounting for nearly 12% of nosocomial infections. Enterococcus faecalis is the most prevalent enterococcal species (85%-89%), whereas Enterococcus faecium accounts for 10%-15% of enterococcal isolates. Only 5% of E. faecalis isolates are resistant to glycopeptides. E. faecium has also been shown to be resistant to nonglycopeptide compounds, such as penicillins (97%), high-level gentamicin (52.1%), and high-level streptomycin (58.3%). Numerous risk factors for vancomycin-resistant enterococci (VRE) have been identified, including as length of hospital- or ICU-stay, proximity to a hospitalized, colonized VRE, patient severity of illness, renal failure, recent surgery, immunosuppression, and organ recipient status. An important risk factor is prior exposure to antibiotics such as vancomycin, ceftazidime, ciprofloxacin, and metronidazole, as well as the number and duration of recent antibiotics. Interventions to reduce nosocomial VRE cross-transmission have also been studied. Using gowns in addition to gloves diminished the incidence of VRE in one study, but had a negligible effect in a second study. Studies have shown that in many cases (> 60%) vancomycin usage is inappropriate. While controlling the use of vancomycin alone has only variably diminished VRE colonization, other efforts such as narrowing the spectrum of antibiotics, antiseptics, and reducing immunosuppression may be salutary. Attempts to eradicate VRE intestinal carriage with enteral agents (bacitracin, tetracycline + rifampin, novobiocin) have been reported but seem to have only a transient effect. Non-antimicrobial interventions such as removal of intravenous or bladder catheters and/or surgical or percutaneous drainage may be beneficial. In addition, the development of new antimicrobial agents such as streptogramins, glycopeptides, everninomicins, and oxazalididones will hopefully play an important role in reducing morbidity from these pathogens.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10091034     DOI: 10.1016/s0732-8893(98)00148-5

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  12 in total

1.  High prevalence of vancomycin-resistant enterococci in Swedish sewage.

Authors:  Aina Iversen; Inger Kühn; Anders Franklin; Roland Möllby
Journal:  Appl Environ Microbiol       Date:  2002-06       Impact factor: 4.792

Review 2.  Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Authors:  H M Lamb; D P Figgitt; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

3.  Occurrence and relatedness of vancomycin-resistant enterococci in animals, humans, and the environment in different European regions.

Authors:  Inger Kühn; Aina Iversen; Maria Finn; Christina Greko; Lars G Burman; Anicet R Blanch; Xavier Vilanova; Albert Manero; Huw Taylor; Jonathan Caplin; Lucas Domínguez; Inmaculada A Herrero; Miguel A Moreno; Roland Möllby
Journal:  Appl Environ Microbiol       Date:  2005-09       Impact factor: 4.792

4.  The vanB2 gene cluster of the majority of vancomycin-resistant Enterococcus faecium isolates from Taiwan is associated with the pbp5 gene and is carried by Tn5382 containing a novel insertion sequence.

Authors:  Jang-Jih Lu; Tein-Yao Chang; Cherng-Lih Perng; Shih-Yi Lee
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

Review 5.  Astonishing diversity of natural surfactants: 2. Polyether glycosidic ionophores and macrocyclic glycosides.

Authors:  Valery M Dembitsky
Journal:  Lipids       Date:  2005-03       Impact factor: 1.880

Review 6.  Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci.

Authors:  Ana Maria Rivera; Helen W Boucher
Journal:  Mayo Clin Proc       Date:  2011-12       Impact factor: 7.616

Review 7.  Newer treatment options for skin and soft tissue infections.

Authors:  Murugan Raghavan; Peter K Linden
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infection.

Authors:  Jeff Alder; Tongchaun Li; Donghui Yu; Larry Morton; Jared Silverman; Xi-Xian Zhang; Ian Critchley; Grace Thorne
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

9.  Antimicrobial resistance of Enterococcus species isolated from produce.

Authors:  Lynette M Johnston; Lee-Ann Jaykus
Journal:  Appl Environ Microbiol       Date:  2004-05       Impact factor: 4.792

10.  A longitudinal study of antimicrobial resistant faecal bacteria in sediments collected from a hospital wastewater system.

Authors:  Jakob Ryd Ottosson; Per-Åke Jarnheimer; Thor Axel Stenström; Björn Olsen
Journal:  Infect Ecol Epidemiol       Date:  2012-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.